Honeywell Aerospace CEO Forecasts Strong Growth Ahead of Standalone Debut
Honeywell Aerospace CEO Jim Currier anticipates significant earnings growth following its spin-off from Honeywell International. The company targets $6.5
Investor topic hub
Markets
Market-moving news across stocks, bonds, currencies, private credit, capital markets, and investor sentiment.
Yield moves and rate-sensitive assets
Equity leadership and sector rotation
Liquidity, credit spreads, and risk appetite
Eli Lilly Shifts Dealmaking Strategy, Fueled by GLP-1 Drug Success
Eli Lilly is strategically deploying its substantial financial gains from GLP-1 drugs like Mounjaro and Zepbound to pursue a more aggressive and diversified acquisition...
CBS Fires Veteran Correspondent Scott Pelley Amid ’60 Minutes’ Editorial Turmoil
Veteran '60 Minutes' correspondent Scott Pelley has been fired by CBS News amidst significant internal turmoil.
Sellers Delist Homes at Fastest Rate Since 2020 Amid Higher Mortgage Rates
Frustrated home sellers nationwide delisted properties in April at a pace not seen since March 2020, driven by higher mortgage rates and weaker consumer...
Morgan Stanley to Open Wealth Management Funnel to External AI Agents
Morgan Stanley will soon allow external AI agents to directly access its stock administration platforms, ShareWorks and Equity Edge.
Private Sector Adds 122,000 Jobs in May, Exceeding Expectations, ADP Reports
The private sector added 122,000 jobs in May, exceeding expectations.
Audemars Piguet Watch Prices Stable Despite Swatch Collaboration Concerns
Audemars Piguet's collaboration with Swatch, the Royal Pop collection, sparked fears of brand dilution.
Barry Diller’s People Inc. Offers to Acquire Casino Giant MGM Resorts for $48.30 Per Share
Barry Diller's People Inc. has made an offer to purchase casino giant MGM Resorts for $48.30 per share.
UAW Strike at Dauch Corp. Threatens General Motors Truck Production
Nearly 1,000 UAW workers at Dauch Corp. in Michigan are on strike, impacting General Motors' pickup truck production.
Akeso and Summit Therapeutics’ Ivonescimab Shows Improved Survival in China Lung Cancer Trial, Fueling Market Debate
Akeso and Summit Therapeutics' experimental lung cancer drug, ivonescimab, demonstrated a 34% reduction in death risk in a late-stage China trial, offering extended survival...